Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
-
REGULATORY HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
-
BUSINESS iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
-
REGULATORY Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
-
REGULATORY CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
-
COMMENTARY A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
July 13, 2026
-
REGULATORY Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
-
BUSINESS Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
-
BUSINESS Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
-
ORGANIZATION FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
-
REGULATORY MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
-
REGULATORY Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
-
REGULATORY Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
-
BUSINESS Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
-
BUSINESS AstraZeneca CSO Urges Global Drug Price “Rebalancing” amid MFN Push
July 8, 2026
-
REGULATORY LDP, Ishin Near Deal on Chuikyo Reform to Bolster Drug Discovery
July 7, 2026
-
COMMENTARY DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
July 6, 2026
-
BUSINESS Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
-
REGULATORY Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
-
BUSINESS Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…